Rogier Rooswinkel, PhD

Rogier is responsible for evaluation and structuring of new investment opportunities across all disease areas with an emphasis on oncology. He was among others closely involved in the investments in Rigontec, Replimune, Enterprise, KaNDy and setting up of the university spin-out Catalym. He currently serves as a board member for Amphista, Catalym, Tessellate, Pheon, Loqus23, Granite and various stealth companies. Previously, Rogier was a board director of Achilles ($ACHL) and an observer at Replimune ($REPL), Enterprise, Prilenia, Nerre and Kandy.

Rogier joined Forbion in 2013. Prior to joining Forbion, Rogier worked as a post-doc at the Netherlands Cancer Institute (NKI), division of immunology. During his studies, Rogier was active as an independent website designer and founded an IT-company.

In 2013 he received his PhD degree Cum Laude from the University of Amsterdam for the work he performed at the NKI. Before that, he received a Master’s degree in Oncology at the VU university of Amsterdam